DB
ZOM

Dmitry Balyasny’s Zomedica Corp. ZOM Stock Holding History

Dmitry Balyasny’s Portfolio ZOM Stock Details ZOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-24,389
Closed -$5K – 3482
2022
Q2 		$5K Buy
24,389
+4,289
+21% +$1.09K ﹤0.01% 2665
2022
Q1 		$7K Buy
+20,100
New +$6.58K ﹤0.01% 2420

Other funds holding ZOM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
PWMG
Pinnacle Wealth Management Group Plymouth, Michigan $214M AUM 20.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Dmitry Balyasny's ZOM Position: Q3 2022 in Review

Dmitry Balyasny sold out of Zomedica Corp. (ZOM) in Q3 2022, closing a stake of 24,389 shares — an estimated $5K sold.

Dmitry Balyasny first reported a position in ZOM in Q1 2022 and held it in 2 quarters. The position peaked at $7K in Q1 2022. 87 funds tracked by Wall St. Rank hold ZOM as of Q3 2022.

  • Dmitry Balyasny reported no remaining Zomedica Corp. position as of Q3 2022 after selling out during the quarter.
  • Dmitry Balyasny sold 24,389 Zomedica Corp. shares in Q3 2022, an estimated $5K.
  • Dmitry Balyasny first reported a position in Zomedica Corp. in Q1 2022 and held it in 2 quarters.
  • Dmitry Balyasny's Zomedica Corp. position peaked at $7K in Q1 2022.
  • 87 funds tracked by Wall St. Rank held Zomedica Corp. as of Q3 2022.

Based on Balyasny Asset Management's 13F filing for Q3 2022, filed 15 Nov 2022.